⌘K
Loading ticker…
Invivyd, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Invivyd, Inc. Common Stock (IVVD) has a 3-month relative strength percentile of 7 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 11.0%, relative volume 4.88×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
7 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
IVVD is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $10M notional. Top 3 carry $20M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $10M |
| XBIState Street SPDR S&P Biotech ETF | 0.10% | $7M |
| VXFVanguard Extended Market ETF | 0.00% | $3M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $743K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IVVD Jan avg: 6.06% median: 0.90% win: 50% σ: 37.62% n: 4 2022-09-14 → 2026-05-29 | IVVD Feb avg: 45.03% median: -10.24% win: 25% σ: 119.83% n: 4 2022-09-14 → 2026-05-29 | IVVD Mar avg: -22.24% median: -27.06% win: 25% σ: 25.64% n: 4 2022-09-14 → 2026-05-29 | IVVD Apr avg: -11.63% median: -2.11% win: 50% σ: 26.48% n: 4 2022-09-14 → 2026-05-29 | IVVD May avg: 19.08% median: 15.62% win: 50% σ: 43.09% n: 4 2022-09-14 → 2026-05-29 | IVVD Jun avg: -35.14% median: -40.22% win: 0% σ: 10.08% n: 3 2022-09-14 → 2026-05-29 (current) | IVVD Jul avg: 17.22% median: 13.64% win: 67% σ: 22.16% n: 3 2022-09-14 → 2026-05-29 | IVVD Aug avg: 11.30% median: 25.68% win: 67% σ: 38.18% n: 3 2022-09-14 → 2026-05-29 | IVVD Sep avg: -2.69% median: 2.23% win: 50% σ: 24.85% n: 4 2022-09-14 → 2026-05-29 | IVVD Oct avg: 16.66% median: 9.57% win: 50% σ: 33.58% n: 4 2022-09-14 → 2026-05-29 | IVVD Nov avg: -7.40% median: -12.45% win: 25% σ: 34.36% n: 4 2022-09-14 → 2026-05-29 | IVVD Dec avg: 22.24% median: -15.99% win: 50% σ: 91.84% n: 4 2022-09-14 → 2026-05-29 |